Akt modulators(Proto-oncogene proteins c-akt modulators), EGFR modulators(Epidermal growth factor receptor erbB1 modulators), MAPKs modulators(Mitogen-activated protein kinase modulators)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease

Active Indication

Metastatic Pancreatic Cancer

Inactive Indication

COVID-19Dermatitis, AtopicHepatitis B, Chronic+ [4]

Originator Organization

Golden Biotechnology Corp.

Active Organization

Golden Biotechnology Corp.

Inactive Organization-

License Organization

Sanova Pharma GesmbH

BNC KOREA, Inc.

McKesson Corp.

+ [1]

Drug Highest PhasePhase 1/2

First Approval Date-

RegulationOrphan Drug (United States), Orphan Drug (European Union)

Structure/Sequence

Molecular FormulaC24H38O4

InChIKeyLJTSIMVOOOLKOL-FNRDIUJOSA-N

CAS Registry1010081-09-0

Clinical Trials associated with Antroquinonol

NCT04523181

/ CompletedPhase 2

A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19

To evaluate the safety and efficacy of antroquinonol treatment of mild to moderate pneumonia due to COVID-19, as measured by the proportion of patients alive and free of respiratory failure.

Start Date15 Oct 2020

Sponsor / Collaborator

Golden Biotechnology Corp.

NCT03823352

/ CompletedPhase 2

Open-label, Non-randomized, Phase IIa Study to Evaluate Efficacy and Safety/Tolerability Profiles of Antroquinonol in Adult Patients With Relapsed Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible

This is a IIa phase IIa open-label, non-randomized clinical trial of Antroquinonol, capsule, 100 mg (Golden Biotechnology Corporation, Taiwan) in patients with AML.

Start Date20 Feb 2019

Sponsor / Collaborator

Golden Biotechnology Corp.

NCT04112147

/ Unknown statusPhase 2IIT

A Randomized, Double-Blind, Dosing-Ranging, Placebo-controlled Trial of Antroquinonol in Patients With Chronic Hepatitis B

Primary Objective:
To evaluate the activity of Antroquinonol in patients with chronic hepatitis B
Secondary Objective:
To assess the mechanism and cytokines change of Antroquinonol in patients with chronic hepatitis B

Start Date10 Aug 2018

Sponsor / Collaborator

Chung Shan Medical University

[+1]

100 Clinical Results associated with Antroquinonol

100 Translational Medicine associated with Antroquinonol

100 Patents (Medical) associated with Antroquinonol

Literatures (Medical) associated with Antroquinonol

01 Jun 2022·EFSA journal. European Food Safety Authority

Safety of freeze‐dried mycelia of Antrodia camphorata as a novel food pursuant to regulation (EU) 2015/2283

Article

Author: Castenmiller, Jacqueline ; Prieto Maradona, Miguel ; Marchelli, Rosangela ; Knutsen, Helle Katrine ; Turla, Emanuela ; Naska, Androniki ; Turck, Dominique ; Pentieva, Kristina ; Frenzel, Thomas ; Bohn, Torsten ; Maciuk, Alexandre ; Heinonen, Marina ; McArdle, Harry J. ; Mangelsdorf, Inge ; Hirsch-Ernst, Karen Ildico ; Tsabouri, Sophia ; Cubadda, Francesco ; De Henauw, Stefaan ; Pelaez, Carmen ; EFSA Panel on Nutrition, Novel Foods and Food Allergens ; Vinceti, Marco ; van Loveren, Henk ; Thies, Frank ; Neuhauser-Berthold, Monika ; Siani, Alfonso ; Poulsen, Morten ; Schlatter, Josef Rudolf

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on freeze-dried mycelia of Antrodia camphorata as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is produced by solid-state cultivation from tissue cultures derived from the fungus Antrodia camphorata. The applicant intends to market the NF in food supplements at a maximum dose of 990 mg per day. The target population is the general population. The NF mainly consists of carbohydrates, proteins and fats, and it contains numerous constituents, such as β-glucans, antroquinonol and triterpenoids. Taking into account the composition of the NF and the proposed conditions of use, the consumption of the NF is not nutritionally disadvantageous. There are no concerns regarding genotoxicity of the NF. Based on a 90-day repeated dose toxicity study and a prenatal developmental toxicity study performed with the NF, the Panel derives a safe level of 16.5 mg/kg body weight per day. The Panel concludes that the NF, freeze-dried mycelia of Antrodia camphorata, is safe at the proposed use level for individuals aged 14 years and above.

01 May 2022·Brain, behavior, & immunity - health

Antroquinonol administration in animal preclinical studies for Alzheimer's disease (AD): A new avenue for modifying progression of AD pathophysiology

Article

Author: Sarah, Lye ; Caitlin, Aust ; Robyn, Griffiths Lyn ; Francesca, Fernandez

Despite the rise of Alzheimer's disease (AD) in an ageing population, no cure is currently available for this disorder. This study assessed the role of a natural compound, Antroquinonol, in modifying the progression of AD when administered at the start and/or before appearance of symptoms and when the disease was well established, in a transgenic animal model. Antroquinonol was administered daily for 8 weeks, in 11 week (early stage) and 9 month (late stage) male transgenic mice (3 times Transgenic mice PS1_M146V, APP_Swe, and tau_P301L, 3 Tg XAD) and their respective aged controls. Behavioural testing (including Elevated Plus Maze Watermaze, Recognition object testing and Y maze) was performed at the end of the drug administration. In addition AD biomarkers (Amyloid beta 42 (Aβ42), tau and phospho-tau levels), oxidative stress and inflammatory markers, were assessed in tested mice brains after their sacrifice at the end of the treatment. When administered before the start of symptoms at 11 weeks, Antroquinonol treatment at 34 mg/kg (D2) and more consistently at 75 mg/kg (D3), had a significant effect on reducing systemic inflammatory markers (Interleukin 1, IL-1β and TNF-α) and AD biomarker (Amyloid Beta 42, Aβ42 and tau) levels in the brain. The reduction of behavioural impairment reported for 3TgXAD mice was observed significantly for the D3 drug dose only and for all behavioural tests, when administered at 11 weeks. Similarly, beneficial effects of Antroquinonol (at higher dose D3) were noted in the transgenic mice in terms of AD biomarkers (tau and phosphorylated-tau), systemic inflammatory (IL-1β), brain anti-inflammatory (Nrf2) and oxidative (3-Nitrotyrosine, 3NT) markers. Improvement of memory impairment was also reported when Antroquinonol (D3) was administered at late stage (9 months). Since Antroquinonol has been used without adverse effects in previous successful clinical trials, this drug may offer a new avenue of treatment to modify AD development and progression.

20 Jan 2022·Journal of industrial microbiology & biotechnologyQ3 · ENGINEERING & TECHNOLOGY

Genetic evidence for the requirements of antroquinonol biosynthesis byAntrodia camphorataduring liquid-state fermentation

Q3 · ENGINEERING & TECHNOLOGY

Article

Author: Song, Xin ; Xiong, Zhiqiang ; Liu, Xiaofeng ; Liang, Lihong ; Li, Hui ; Xia, Yongjun ; Ai, Lianzhong ; Zhou, Xuan ; Wang, Guangqiang

Abstract:

The solid-state fermentation of Antrodia camphorata could produce a variety of ubiquinone compounds, such as antroquinonol (AQ). However, AQ is hardly synthesized during liquid-state fermentation (LSF). To investigates the mechanism of AQ synthesis, three precursors (ubiquinone 0 UQ0, farnesol and farnesyl diphosphate FPP) were added in LSF. The results showed that UQ0 successfully induced AQ production; however, farnesol and FPP could not induce AQ synthesis. The precursor that restricts the synthesis of AQ is the quinone ring, not the isoprene side chain. Then, the Agrobacterium-mediated transformation system of A. camphorata was established and the genes for quinone ring modification (coq2-6) and isoprene synthesis (HMGR, fps) were overexpressed. The results showed that overexpression of genes for isoprene side chain synthesis could not increase the yield of AQ, but overexpression of coq2 and coq5 could significantly increase AQ production. This is consistent with the results of the experiment of precursors. It indicated that the A. camphorata lack the ability to modify the quinone ring of AQ during LSF. Of the modification steps, prenylation of UQ0 is the key step of AQ biosynthesis. The result will help us to understand the genetic evidence for the requirements of AQ biosynthesis in A. camphorata.

News (Medical) associated with Antroquinonol

19 Jan 2024

·www.goldenbiotech.com

ASCO GI 2024: Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients (Yahoo Finance)

ASCO GI 2024: Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients (Yahoo Finance) TAIPEI, Jan. 18, 2024 /PRNewswire/ -- Golden Biotechnology Corp. (TPEX 4132) ("GoldenBiotech", GBC), an advanced biopharmaceutical drug development company, had unveiled the findings of its Phase II clinical trial investigating Antroquinonol (HOCENA) in combination with the standard of care (SOC): nab-paclitaxel + gemcitabine, as first-line treatment for metastatic pancreatic cancer. The trial showed a positive median overall survival (mOS) of 14.1 months, which is a substantial increase compared to 8.5 months mOS observed in the standard of care Phase III clinical study (nab-paclitaxel + gemcitabine). Notably, when compared to current first-line treatment options for this very difficult to treat cancer, there was a highly significant survival advantage of patients treated with oral Antroquinonol in combination with SOC. Metastatic Pancreatic Cancer remains a devastating disease with very low survival rate and significant unmet medical needs in terms of treatment options. Photo of Antroquinonol.(Golden Biotechnology Corp.) The ASCO Gastrointestinal Cancers Symposium 2024 Committee has selected Golden Biotech's Phase 2 Study, titled "A Phase I/II study of Antroquinonol in combination with Nab-Paclitaxel and Gemcitabine for patients with metastatic pancreatic cancer," for poster presentation. This multinational study, registered under NIH Clinical Trial Registration Number NCT03310632, employed a single-arm, open-label design with participating sites in the United States, South Korea, and Taiwan. The study revealed clinically meaningful responses in subjects treated with Antroquinonol in combination with the standard of care. The treatment demonstrated significantly longer overall survival (median OS) and OS rates at both 6 and 12 months when compared to the standard of care Phase III study. The OS figures were 14.1, 8.5, and 6.7 months for (Antroquinonol + nab-paclitaxel + gemcitabine), (nab-paclitaxel + gemcitabine), and gemcitabine alone, respectively. The corresponding OS rates at 6 months were 85.5%, 67%, and 55%, while the rates at 12 months were 62.2%, 35%, and 22%. In addition, Antroquinonol in combination with the standard of care surpassed the efficacy of another chemotherapy regimen, FOLFIRINOX, in terms of median OS and OS rates (Antroquinonol + standard of care vs FOLFIRINOX: OS= 14.1 vs 11.1 months; OS rate at 6 months=85.5% vs 76%; OS rate at 12 months=62.2% vs 48%). The trial results also showed an mPFS of 5.3 months and a 6-month PFS rate of 41.7% for Antroquinonol in combination with the standard of care drugs. The American Society of Clinical Oncology (ASCO) Committee have defined Clinically Meaningful Goals for clinical trials in Pancreas, Breast, Lung, and Colorectal Cancers. For Pancreatic Cancer patients eligible for treatment with Gemcitabine or Gemcitabine/Nab-paclitaxel, the current baseline median overall survival is estimated to range from 8 to 9 months. It is considered "clinically meaningful" if the minimum improvement over current overall survival is between 3 to 4 months. Golden Biotech's Antroquinonol has gained recognition for its groundbreaking work in the field of cancer treatment. It has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Pancreatic Cancer, Acute Myeloid Leukemia (AML), and Hepatocellular Carcinoma (liver cancer), as well as ODD by the EMA for Pancreatic Cancer. These acknowledgments underscore the potential of Antroquinonol in addressing the high-unmet medical needs associated with these challenging diseases. When compared to gemcitabine and other existing first-line therapies for metastatic pancreatic cancer, Antroquinonol in combination with the standard of care exhibited a significant survival advantage. Additionally, hematological adverse events (AEs) induced by nab-paclitaxel and gemcitabine, such as neutropenia, thrombocytopenia, anemia, and leukopenia, were substantially improved across all grade levels. No additional safety concerns were observed during the study. By combining nab-paclitaxel and gemcitabine with Antroquinonol, the incidence of hematological side effects also decreased across all grades. The results of this clinical trial may be a potential game changer for metastatic pancreatic cancer. Antroquinonol in combination with the standard of care may provide patients with significantly improved median overall survival and reduced hematological side-effects. Providing new hope for patients everywhere, for this very difficult to treat cancer. Media Contact: pr@goldenbiotech.com FORWARD-LOOKING STATEMENTS: The statements contained herein may contain certain forward-looking statements relating to Golden Biotechnology Corporation (the “Company”) that are based on the current beliefs and expectations of the Company’s management as well as assumptions made by and information currently available to the Company’s management. These forward-looking statements include, but are not limited to, statements relating to the Company’s business prospects, future developments, trends and conditions in the industry and geographical markets in which the Company operates; the Company’s inventions, patents, patent applications, strategies, plans, objectives and goals; the Company’s ability to control costs; and statements relating to prices, volumes, operations, margins, overall market trends, risk management and exchange rates. These statements can be identified by the use of words such as “anticipate,” “estimate,” “believe,” “continue,” “could,” “intend,” “may,” “plan,” “potential,” “predict,” “should,” “seek,” “will,” “expect,” “objective,” “projection,” “forecast,” “goal,” “guidance,” “outlook,” “effort,” “target” or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update or reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events. All forward-looking statements herein are qualified by these cautionary statements and there can be no assurance that the actual results or anticipated developments will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company’s business or operations. https://finance.yahoo.com/news/asco-gi-2024-golden-biotechs-101500456.html

Clinical ResultASCOOrphan DrugPhase 2Phase 3

18 Jan 2024

·www.fiercebiotech.com

Mushroom-derived drug posts improved survival data in Golden Biotech’s pancreatic cancer trial

Pancreatic cancer. Golden Biotechnology has shared updated data on its mushroom-derived drug candidate in metastatic pancreatic cancer, linking first-line use of the molecule to median overall survival (OS) of 14.1 months. People with metastatic pancreatic cancer lack good options, to the extent that the National Institutes of Health recommends that all newly diagnosed patients should consider enrolling in clinical trials. Chemotherapy remains the least bad option for many patients, with the FOLFIRINOX cocktail and gemcitabine-nab-paclitaxel combination respectively chalking up median OS figures of 11.1 months and 8.5 months. Another chemotherapy regimen, NALIRIFOX, also achieved a median OS of 11.1 months last year. Golden Biotech is presenting data on its attempt to clear that OS bar at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium this week. The median OS in metastatic pancreatic cancer patients who received its drug antroquinonol, along with gemcitabine and nab-paclitaxel as a first-line treatment was 14.1 months. Median progression-free survival clocked in at 5.3 months. The OS has increased since an earlier look at the data, when it came in at 12.6 months. In 2014, an ASCO committee said a 4-5 month improvement over FOLFIRINOX, or 3-4 month edge over gemcitabine-nab-paclitaxel, would be clinically meaningful. Research suggests more patients are eligible for gemcitabine-nab-paclitaxel than the more effective FOLFIRINOX. In the absence of a control arm, it is impossible to tell whether adding antroquinonol to the treatment mix improves on the OS achieved by chemotherapy. Investors appeared unmoved, with little change in the Taiwanese biotech’s share price on the Taipei Exchange. Golden Biotech’s statement lacks a close look at the safety and tolerability results. An earlier cut of the data showed the rates of neutropenia, thrombocytopenia and anemia were lower in the antroquinonol group than in an earlier chemotherapy trial, although the rates of vomiting and diarrhea were higher. Antroquinonol is a ubiquinone derivative found in a mushroom that grows on a tree of Taiwan. Evidence that the molecule blocks RAS signaling has spurred Golden Biotech to advance the molecule in pancreatic cancer. Other biotechs are going after the cancer by targeting KRAS, NTRK fusions, RET and other drivers of pancreatic tumors.

Clinical ResultASCOPhase 3

18 Jan 2024

·www.biospace.com

ASCO GI 2024: Golden Biotech's Antroquinonol Shows Significantly Prolonged Survival in Untreated Metastatic Pancreatic Cancer Patients

TAIPEI, Jan. 18, 2024 /PRNewswire/ -- Golden Biotechnology Corp.(TPEX 4132) ("GoldenBiotech", GBC), an advanced biopharmaceutical drug development company, had unveiled the findings of its Phase II clinical trial investigating Antroquinonol (HOCENA) in combination with the standard of care (SOC): nab-paclitaxel + gemcitabine, as first-line treatment for metastatic pancreatic cancer. The trial showed a positive median overall survival (mOS) of 14.1 months, which is a substantial increase compared to 8.5 months mOS observed in the standard of care Phase III clinical study (nab-paclitaxel + gemcitabine). Notably, when compared to current first-line treatment options for this very difficult to treat cancer, there was a highly significant survival advantage of patients treated with oral Antroquinonol in combination with SOC. Metastatic Pancreatic Cancer remains a devastating disease with very low survival rate and significant unmet medical needs in terms of treatment options. The ASCO Gastrointestinal Cancers Symposium 2024 Committee has selected Golden Biotech's Phase 2 Study, titled "A Phase I/II study of Antroquinonol in combination with Nab-Paclitaxel and Gemcitabine for patients with metastatic pancreatic cancer," for poster presentation. This multinational study, registered under NIH Clinical Trial Registration Number NCT03310632, employed a single-arm, open-label design with participating sites in the United States, South Korea, and Taiwan. The study revealed clinically meaningful responses in subjects treated with Antroquinonol in combination with the standard of care. The treatment demonstrated significantly longer overall survival (median OS) and OS rates at both 6 and 12 months when compared to the standard of care Phase III study. The OS figures were 14.1, 8.5, and 6.7 months for (Antroquinonol + nab-paclitaxel + gemcitabine), (nab-paclitaxel + gemcitabine), and gemcitabine alone, respectively. The corresponding OS rates at 6 months were 85.5%, 67%, and 55%, while the rates at 12 months were 62.2%, 35%, and 22%. In addition, Antroquinonol in combination with the standard of care surpassed the efficacy of another chemotherapy regimen, FOLFIRINOX, in terms of median OS and OS rates (Antroquinonol + standard of care vs FOLFIRINOX: OS= 14.1 vs 11.1 months; OS rate at 6 months=85.5% vs 76%; OS rate at 12 months=62.2% vs 48%). The trial results also showed an mPFS of 5.3 months and a 6-month PFS rate of 41.7% for Antroquinonol in combination with the standard of care drugs. The American Society of Clinical Oncology (ASCO) Committee have defined Clinically Meaningful Goals for clinical trials in Pancreas, Breast, Lung, and Colorectal Cancers. For Pancreatic Cancer patients eligible for treatment with Gemcitabine or Gemcitabine/Nab-paclitaxel, the current baseline median overall survival is estimated to range from 8 to 9 months. It is considered "clinically meaningful" if the minimum improvement over current overall survival is between 3 to 4 months. Golden Biotech's Antroquinonol has gained recognition for its groundbreaking work in the field of cancer treatment. It has been granted Orphan Drug Designation (ODD) by the FDA for the treatment of Pancreatic Cancer, Acute Myeloid Leukemia (AML), and Hepatocellular Carcinoma (liver cancer), as well as ODD by the EMA for Pancreatic Cancer. These acknowledgments underscore the potential of Antroquinonol in addressing the high-unmet medical needs associated with these challenging diseases. When compared to gemcitabine and other existing first-line therapies for metastatic pancreatic cancer, Antroquinonol in combination with the standard of care exhibited a significant survival advantage. Additionally, hematological adverse events (AEs) induced by nab-paclitaxel and gemcitabine, such as neutropenia, thrombocytopenia, anemia, and leukopenia, were substantially improved across all grade levels. No additional safety concerns were observed during the study. By combining nab-paclitaxel and gemcitabine with Antroquinonol, the incidence of hematological side effects also decreased across all grades. The results of this clinical trial may be a potential game changer for metastatic pancreatic cancer. Antroquinonol in combination with the standard of care may provide patients with significantly improved median overall survival and reduced hematological side-effects. Providing new hope for patients everywhere, for this very difficult to treat cancer FORWARD-LOOKING STATEMENTS: The statements contained herein may contain certain forward-looking statements relating to Golden Biotechnology Corporation (the "Company") that are based on the current beliefs and expectations of the Company's management as well as assumptions made by and information currently available to the Company's management. These forward-looking statements include, but are not limited to, statements relating to the Company's business prospects, future developments, trends and conditions in the industry and geographical markets in which the Company operates; the Company's inventions, patents, patent applications, strategies, plans, objectives and goals; the Company's ability to control costs; and statements relating to prices, volumes, operations, margins, overall market trends, risk management and exchange rates. These statements can be identified by the use of words such as "anticipate," "estimate," "believe," "continue," "could," "intend," "may," "plan," "potential," "predict," "should," "seek," "will," "expect," "objective," "projection," "forecast," "goal," "guidance," "outlook," "effort," "target" or the negative of these terms or other comparable terms. However, the absence of these words does not mean that the statements are not forward-looking. These forward-looking statements are, by their nature, subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update or reflect subsequent events or circumstances, changes in expectations or the occurrence of unanticipated events. All forward-looking statements herein are qualified by these cautionary statements and there can be no assurance that the actual results or anticipated developments will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company's business or operations. View original content to download multimedia: SOURCE Golden Biotechnology Corp. Company Codes: Gretai:4132, Taiwan:4132.TWO, Taiwan:4132

Clinical ResultASCOOrphan DrugPhase 2Phase 3

100 Deals associated with Antroquinonol

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12326

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
COVID-19	Phase 2	United States	Golden Biotechnology Corp.	15 Oct 2020
COVID-19	Phase 2	Argentina	Golden Biotechnology Corp.	15 Oct 2020
COVID-19	Phase 2	Peru	Golden Biotechnology Corp.	15 Oct 2020
Relapsing acute myeloid leukemia	Phase 2	Russia	Golden Biotechnology Corp.	20 Feb 2019
Hepatitis B, Chronic	Phase 2	Taiwan Province	Golden Biotechnology Corp.	01 Aug 2018
Dermatitis, Atopic	Phase 2	Taiwan Province	Golden Biotechnology Corp.	17 Jul 2018
Metastatic Pancreatic Cancer	Phase 2	United States	Golden Biotechnology Corp.	01 Dec 2017
Metastatic Pancreatic Cancer	Phase 2	Taiwan Province	Golden Biotechnology Corp.	01 Dec 2017
Hypercholesterolemia	Phase 2	Taiwan Province	Golden Biotechnology Corp.	01 May 2016
metastatic non-small cell lung cancer	Phase 2	United States	Golden Biotechnology Corp.	01 Oct 2013

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03310632 (NEWS) Manual	Phase 2	Pancreatic Cancer	-	Antroquinonol+白蛋白结合型紫杉醇+吉西他滨	ayhlulqgye(djsiivuhmz) = smkzqbdvga msxyvntswm (fjvuagoszz ) View more	Positive	19 Jan 2024
				白蛋白结合型紫杉醇+吉西他滨	ayhlulqgye(djsiivuhmz) = ljjmvnubnr msxyvntswm (fjvuagoszz ) View more
NCT04523181 (CTgov)	Phase 2	COVID-19	124	Antroquinonol (Antroquinonol With SOC)	acujzfloxu = acimjdppqs kbvlhihddg (qtiomsmsyr, lizorupcnz - hxqhdiapuo) View more	-	13 Dec 2023
				Placebo (Placebo With SOC)	acujzfloxu = wnjhxnzmyw kbvlhihddg (qtiomsmsyr, dhqokzgxfe - jllfabcsfz) View more
NCT04523181 (PRNewswire) Manual	Phase 2	COVID-19	124	Antroquinonol	younvsuqyp(tzmolqfmqg) = spchpccyzl gbnyvjvysu (fworfluqjy ) View more	Positive	07 Jan 2022
				Placebo	-
NCT03823352 (GHAML-2-001, ASCO2021)	Phase 2	Relapsing acute myeloid leukemia	12	Antroquinonol 200 mg BID	bchjcibchs(mmifurkuap) = ngtrkaftom qmvjbtqbry (kpfslyxrle )	Positive	28 May 2021
NCT02719028 (CTgov)	Phase 2	Hypercholesterolemia	120	placebo (Placebo)	owarrcantf(gmwybojxqw) = odqtcbspnm zkgbhmnzzq (djiaatdhly, qphkpzgxli - fltplxljjt) View more	-	20 Dec 2019
				placebo+Antroquinonol (Antroquinonol 50 mg PO)	owarrcantf(gmwybojxqw) = fdnrifeuai zkgbhmnzzq (djiaatdhly, dgbxvhbsck - rboiuwbpko) View more
NCT02047344 (ASCO 12019 \| ASCO 22019) Manual	Phase 2	Non-Small Cell Lung Cancer Last line	30	antroquinonol (2 prior chemotherapy)	vyjtyjrqrf(hyjoisazuk) = mehwkylktj isyvqanrcb (qebnnlfzgq, 5.0 - 31.1)	Positive	31 May 2019
				antroquinonol (more than 2 prior chemotherapy)	vyjtyjrqrf(hyjoisazuk) = jqcojvweco isyvqanrcb (qebnnlfzgq, 6.0 - 14.1) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis